NAOR

Company Overview

Snapshot

Founded in July 2020 by Co-founder & CSO Naama Geva-Zatorsky, NAOR operates with 1–10 employees. The company has completed two funding rounds at the Pre-Seed and Seed stages. In March 2024, NAOR ceased operations.

Business overview

NAOR develops a platform for rapid RNA diagnosis of COVID-19 and other pathogens, utilizing a one-step nucleic acid amplification method for high sensitivity and specificity. Its technology combines biochemistry, electronics, and artificial intelligence to deliver lab-grade results in field settings such as airports, schools, and workplaces, with capabilities for at-home testing. The company serves the Health Tech & Life Sciences sector, with a focus on digital healthcare and medical diagnostics.

Strategic signal

NAOR ceased operations in March 2024. This indicates a significant shift in the company's trajectory, signaling to investors and innovation teams that the venture is no longer active in the market.

Company Intelligence Q&A

What is NAOR's primary focus?

NAOR focuses on developing decentralized rapid RNA diagnostic solutions for COVID-19 and other pathogens, providing high-sensitivity and specificity testing for various environments.

When was NAOR founded?

NAOR was founded in July 2020.

What is the current operational status of NAOR?

NAOR ceased to operate in March 2024 and is currently non-active.

Who is a key founder of NAOR?

Naama Geva-Zatorsky is a Co-founder & CSO of NAOR.

What types of markets does NAOR's technology address?

NAOR's technology is designed for high-volume lab-grade results in field settings like airports, schools, and workplaces, and can also be used for at-home testing.